These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Current and Emerging Treatments for Metastatic Renal Cell Carcinoma. Cavaliere C; D'Aniello C; Pepa CD; Pisconti S; Berretta M; Facchini G Curr Cancer Drug Targets; 2018; 18(5):468-479. PubMed ID: 28183256 [TBL] [Abstract][Full Text] [Related]
9. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173 [TBL] [Abstract][Full Text] [Related]
10. Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy. Diamond E; Molina AM; Carbonaro M; Akhtar NH; Giannakakou P; Tagawa ST; Nanus DM Crit Rev Oncol Hematol; 2015 Dec; 96(3):518-26. PubMed ID: 26321263 [TBL] [Abstract][Full Text] [Related]
12. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma. Hagiwara M; Hackshaw MD; Oster G J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437 [TBL] [Abstract][Full Text] [Related]
13. Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers. Castellano D; Ravaud A; Schmidinger M; De Velasco G; Vazquez F Cancer Treat Rev; 2013 May; 39(3):230-40. PubMed ID: 22647546 [TBL] [Abstract][Full Text] [Related]
14. Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies: overall results from a large cohort of patients. Procopio G; Testa I; Verzoni E; Iacovelli R; Grassi P; Galli G; De Braud F; Saravia D; Salvioni R Oncology; 2015; 88(3):133-8. PubMed ID: 25377648 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia. Mihajlović J; Pechlivanoglou P; Sabo A; Tomić Z; Postma MJ Clin Ther; 2013 Dec; 35(12):1909-22. PubMed ID: 24238790 [TBL] [Abstract][Full Text] [Related]
16. Current systemic management of metastatic renal cell carcinoma - first line and second line therapy. Wright I; Kapoor A Curr Opin Support Palliat Care; 2011 Sep; 5(3):211-21. PubMed ID: 21725244 [TBL] [Abstract][Full Text] [Related]
17. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma. Ainsworth NL; Lee JS; Eisen T Expert Rev Anticancer Ther; 2009 Dec; 9(12):1793-805. PubMed ID: 19954291 [TBL] [Abstract][Full Text] [Related]
18. Immunotherapy and targeted therapies in metastatic renal cell carcinoma: is there a preferred sequence? Giuliani J; Drudi F Cancer Biother Radiopharm; 2012 Oct; 27(8):513-8. PubMed ID: 22738404 [TBL] [Abstract][Full Text] [Related]
19. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Bellmunt J; Négrier S; Escudier B; Awada A; Aapro M; Crit Rev Oncol Hematol; 2009 Jan; 69(1):64-72. PubMed ID: 18774306 [TBL] [Abstract][Full Text] [Related]